Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189565 | 0.85 | ALDH1A1 (0.30) | ALDH1A1LMNASMN1; SMN2MAPK14 | |
| SCHEMBL27189528 | 0.83 | MAPK14 (0.37) | ALDH1A1MAPK14 | |
| SCHEMBL27189526 | 0.76 | BRPF1 (0.38) | HTR1AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4393222 | 0.76 | HTR1A (0.40) | HTR1AALDH1A1LMNASMN1; SMN2MAPK14 | |
| SCHEMBL31077708 | 0.70 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPK14 | |
| SCHEMBL25748906 | 0.70 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPK14 | |
| SCHEMBL25748764 | 0.70 | HTR1A (0.39) | HTR1AALDH1A1LMNAMAPK14 | |
| SCHEMBL25029922 | 0.69 | HTR1A (0.67) | HTR1A | |
| SCHEMBL25748940 | 0.68 | CES2 (0.36) | ALDH1A1LMNASMN1; SMN2MAPK14 | |
| SCHEMBL25678359 | 0.68 | HTR2A (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2025-02-20 | — | — | US | disclosed |
| CN-117897376-A | Heterocyclic compounds and process for preparing same | 光明智慧生物科学公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4347561-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | Bright Minds Biosciences Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022246554-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | OPRL1, OPRK1, CNR2 | HTR1A 306/4885ALDH1A1 371/4885LMNA 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.